Literature DB >> 25943411

Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder.

Adam Wysokiński1, Dominik Strzelecki2, Iwona Kłoszewska3.   

Abstract

AIMS: The aim of this study is to investigate differences in triglycerides (TGA), cholesterol (TC), HDL, LDL and glucose (FPG) levels in patients with acute schizophrenia, unipolar depression, bipolar depression and bipolar mania.
RESULTS: Results for 2305 Caucasian patients were included in the study (1377 women, 59.7%; mean age 45.6). Mean TGA level was: schizophrenia: 139.9±90.6 mg/dL, unipolar depression: 125.4±70.8 mg/dL, bipolar disorder: 141.1±81.9 mg/dL, bipolar depression: 147.7±82.8 mg/dL mg/dL, bipolar mania: 120.2±76.1 mg/dL, inter-group differences were significant (p<0.001). Mean TC level was: schizophrenia: 188.5±40.4 mg/dL, unipolar depression: 198.8±50.7 mg/dL, bipolar disorder: 194.4±48.3 mg/dL, bipolar depression: 198.9±48.8 mg/dL, bipolar mania: 180.1±43.8 mg/dL, inter-group differences were significant (p<0.001). Mean HDL level was: schizophrenia: 45.3±13.9 mg/dL, unipolar depression: 48.1±14.8 mg/dL, bipolar disorder: 45.4±15.3 mg/dL, bipolar depression: 45.1±15.4 mg/dL, bipolar mania: 46.4±15.1 mg/dL, inter-group differences were significant (p<0.001). Mean LDL level was: schizophrenia: 115.4±34.7 mg/dL, unipolar depression: 125.7±44.1 mg/dL, bipolar disorder: 120.9±42.1 mg/dL, bipolar depression: 124.5±43.1 mg/dL, bipolar mania: 109.3±36.9 mg/dL, inter-group differences were significant (p<0.001). Mean FPG level was: schizophrenia: 95.9±24.9 mg/dL, unipolar depression: 94.8±22.9 mg/dL, bipolar disorder: 97.2±24.4 mg/dL, bipolar depression: 98.3±25.3 mg/dL, bipolar mania: 93.9±21.1 mg/dL, inter-group differences were not significant (p=0.08). Odds ratios for glucose and lipids abnormalities, correlations with age, sex distribution in diagnostic groups for normal ranges of glucose and lipids, differences in glucose and lipids levels between the age groups were also calculated.
CONCLUSIONS: Our results confirm that there is a high prevalence of lipid and glucose abnormalities in patients with schizophrenia and mood disorders (both unipolar and bipolar). However, we have demonstrated that these diagnostic groups differ in terms of types and frequency of these metabolic dysfunctions. Women and patients aged 40+ are at particularly high risk.
Copyright © 2015 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Depression; Glucose; Lipid profile; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25943411     DOI: 10.1016/j.dsx.2015.04.004

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  23 in total

1.  Synaptotagmin-7 deficiency induces mania-like behavioral abnormalities through attenuating GluN2B activity.

Authors:  Qiu-Wen Wang; Si-Yao Lu; Yao-Nan Liu; Yun Chen; Hui Wei; Wei Shen; Yan-Fen Chen; Chong-Lei Fu; Ying-Han Wang; Anbang Dai; Xuan Huang; Fred H Gage; Qi Xu; Jun Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

2.  Morus nigra and its major phenolic, syringic acid, have antidepressant-like and neuroprotective effects in mice.

Authors:  Ana Paula Dalmagro; Anderson Camargo; Ana Lúcia Bertarello Zeni
Journal:  Metab Brain Dis       Date:  2017-08-18       Impact factor: 3.584

3.  Synaptotagmin-7 is a key factor for bipolar-like behavioral abnormalities in mice.

Authors:  Wei Shen; Qiu-Wen Wang; Yao-Nan Liu; Maria C Marchetto; Sara Linker; Si-Yao Lu; Yun Chen; Chuihong Liu; Chongye Guo; Zhikai Xing; Wei Shi; John R Kelsoe; Martin Alda; Hongwei Wang; Yi Zhong; Sen-Fang Sui; Mei Zhao; Yiming Yang; Shuangli Mi; Liping Cao; Fred H Gage; Jun Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-10       Impact factor: 11.205

4.  The role of adipokines in the rapid antidepressant effects of ketamine.

Authors:  R Machado-Vieira; P W Gold; D A Luckenbaugh; E D Ballard; E M Richards; I D Henter; R T De Sousa; M J Niciu; P Yuan; C A Zarate
Journal:  Mol Psychiatry       Date:  2016-04-05       Impact factor: 15.992

5.  Increased Global-Brain Functional Connectivity Is Associated with Dyslipidemia and Cognitive Impairment in First-Episode, Drug-Naive Patients with Bipolar Disorder.

Authors:  Pan Pan; Yan Qiu; Ziwei Teng; Sujuan Li; Jing Huang; Hui Xiang; Hui Tang; Jindong Chen; Chujun Wu; Kun Jin; Bolun Wang; Feng Liu; Haishan Wu; Wenbin Guo
Journal:  Neural Plast       Date:  2021-06-05       Impact factor: 3.599

Review 6.  Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications.

Authors:  Ellen F Charles; Christophe G Lambert; Berit Kerner
Journal:  Int J Bipolar Disord       Date:  2016-07-07

7.  Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study.

Authors:  Henriette Thisted Horsdal; Michael Eriksen Benros; Ole Köhler-Forsberg; Jesper Krogh; Christiane Gasse
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-28       Impact factor: 2.570

8.  Low serum levels of High-Density Lipoprotein cholesterol (HDL-c) as an indicator for the development of severe postpartum depressive symptoms.

Authors:  Raji Ramachandran Pillai; Anand Babu Wilson; Nancy R Premkumar; Shivanand Kattimani; Haritha Sagili; Soundravally Rajendiran
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

9.  Physical Activity and Body Composition Are Associated With Severity and Risk of Depression, and Serum Lipids.

Authors:  Claudia von Zimmermann; Merle Winkelmann; Tanja Richter-Schmidinger; Christiane Mühle; Johannes Kornhuber; Bernd Lenz
Journal:  Front Psychiatry       Date:  2020-06-05       Impact factor: 4.157

10.  Does Blood Flow Change according to Mood? Blood Rheology in Bipolar Disorder.

Authors:  Tevfik Kalelioglu; Murat Kocabiyik; Burcu Kok; Pelin Unalan; Sule Sozen; Ozge Yuksel; Nesrin Karamustafalioglu
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.